At Dennis Partners, we know regulatory recruiting. We are committed to creating and maintaining partnerships with our clients while upholding the highest standards of professionalism and ethics. Our team interacts within the marketplace on a daily basis, giving us the ability to locate, screen, and recommend exceptional individuals to your firm. We know how to identify the top performers. Our strength is partnering with you and your business to develop a solution and meet demands for growth while improving efficiency. Let our advanced expertise find the top professionals in the industry to provide a competitive edge to your company.
We have your specialization covered
Contract-to-hire evaluation process
We're on your side
Complete back office support
Our process is cost-effective
Dennis Partner’s focus on only regulatory affairs searches gives them a very good sense of the market, the available talent, and who matches the role. They worked with us diligently to find the right candidate and we ended up making an exceptional hire.
We take the time to evaluate your needs beyond a job description
We identify top talent from our research and competitive analysis
We analyze the talent to match candidates on a deeper level
We go beyond the hire by offering extensive post placement services
Does your company have immediate top-tier talent needs?
Meet Our Team
Here are the top regulatory news stories this week: The FDA approved Amgen’s biosimilar to Roche’s cancer treatment Avastin (bevacizumab). Amgen’s biosimilar was approved under the brand name Mvasi (bevacizumab-awwb): http://www.raps.org/Regulatory-Focus/News/2017/09/14/28467/FDA-Approves-First-Biosimilar-Cancer-Treatment/ FDA commissioner Scott Gottlieb announced Tuesday that the agency will release guidance to close a loophole that allows companies to avoid their obligation to[…]
Summer is over and there has been a flurry of new regulatory news this week including new approvals and clinical holds. Also, there were a few new partnership announcements and a major layoff at Eli Lilly. Here is my summary of the top news stories this week: Pfizer has secured approval from the FDA for[…]
I’m publishing my blog a day early due to the long holiday weekend, and wow this has been quite a week in regulatory news. The FDA approved the first CAR-T therapy, along with two new novel drugs, a new biosimilar, and a couple of supplemental approvals for new indications. The FDA also sent two refuse-to-file[…]
There were a few new approvals this week, plus some new FDA guidances. Here are the top regulatory stories for you to follow this week… Ironwood Pharmaceuticals announced FDA Approval of DUZALLO (Lesinurad And Allopurinol) for the treatment of hyperuricemia in patients with uncontrolled gout. https://www.biospace.com/News/ironwood-announces-fda-approval-of-duzallo/466949/source=MoreNews Adamas Pharmaceuticals reported that the FDA has approved GOCOVRI[…]
The new FDA commissioner Scott Gottlieb said brand name drug companies are “gaming the system” to block generic competition and vowed to do something about it. https://www.usatoday.com/story/news/politics/2017/08/15/fda-chief-says-drug-makers-gaming-system-slow-generic-competition-vows-action/568698001/ The EMA Committee for Human Medicinal Products (CHMP) adopted an updated guideline on what manufacturing process information should be included in the marketing authorization application (MAA). http://raps.org/Regulatory-Focus/News/2017/08/14/28239/EMA’s-CHMP-Adopts-Updated-Guideline-on-Manufacture-of-Finished-Dosage-Form Pfizer[…]
There have not been any new drug approvals so far this week but the FDA granted a few new Orphan Drug Designations and Priority Reviews. Here is my summary of the top regulatory news stories this week for pharma and biotech: The FDA is on track for most generic drug approvals ever for Fiscal Year[…]
The July Employment Situation Report from the Bureau of Labor Statistics revealed a 0.1 percent decline in the U.S.’s unemployment rate – to 4.3 percent – and a gain of 209,000 jobs in total nonfarm payroll employment. According to Markets Insider, projections for the unemployment rate’s small decline were spot-on, while economists’ estimate of jobs[…]
Recently, some large companies have curtailed the ability of their employees to work from home, now asking staff to work in corporate offices. These changes are focused on driving increased collaboration, creativity, mentoring and innovation, but may alienating top talent in the executive, managerial and professional labor market – a sector that has been candidate-driven[…]
There was a lot of regulatory news this week including an extension of the PDUFA bill, FDA approval of two New Molecular Entities, and an approval of the first treatment for Chronic Graft Versus Host Disease. Here is my summary of the top regulatory stories this week: The US Senate passed a bipartisan bill to[…]
There were several guidance updates from the FDA this week along with several new medicine approvals by the EMA. And the anticipated FDA layoffs have been delayed for now. Here is my summary of the top regulatory stories this week: 1. FDA Commissioner Scott Gottlieb said he will delay issuing layoff notices until after September[…]